Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology

04 Mar, 2021

Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology
Photo by Alex Knight on Unsplash

– Janux Therapeutics announced the close of a $56m Series A financing.
– The financing was led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors, Bregua and Correlation Ventures.
– In conjunction with the financing, Peter Thompson, M.D., partner at OrbiMed, and Jake Simson, Ph.D., partner at RA Capital Management, will join the Board of Directors.
– Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology is designed to overcome specific limitations of current T cell immuno-oncology therapies.

Health Diagnostics North America Pharmaceutical Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: